StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Brookline Capital Management reiterated a buy rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, April 5th.

Immunic Stock Up 2.4 %

NASDAQ IMUX opened at $1.26 on Friday. The firm has a market capitalization of $113.50 million, a PE ratio of -0.60 and a beta of 2.07. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.26. Immunic has a twelve month low of $0.95 and a twelve month high of $3.11.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. On average, research analysts anticipate that Immunic will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Innovis Asset Management LLC increased its stake in shares of Immunic by 46.3% in the third quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock worth $401,000 after purchasing an additional 86,217 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Immunic by 26.8% during the 3rd quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock valued at $1,111,000 after buying an additional 159,973 shares in the last quarter. RTW Investments LP boosted its holdings in Immunic by 0.9% in the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after buying an additional 40,796 shares during the period. Sweet Financial Partners LLC purchased a new stake in Immunic in the 4th quarter worth $45,000. Finally, Gratus Capital LLC raised its holdings in Immunic by 15.1% during the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after acquiring an additional 254,999 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.